Armis Biopharma, Inc. is a biopharmaceutical company with a growing pipeline of non-systemic, non-resistant anti-infective therapeutics designed to address antibiotic resistance and healthcare-associated infections. Our mission is to decrease the quantity and severity of infections that cause human suffering and death through the creation and development of novel, targeted, antimicrobial therapies. The Company’s lead technology, Veriox™, is first-of-its-kind, and features an undefeatable Mechanism of Action (M of A) effective against Gram+ and Gram- bacteria, viruses, fungi, spores and chemical/biological warfare pathogens. Our technology delivers highly efficacious concentrations of antimicrobial agents with reduced possibility of systemic toxicity.